Data as of Q4 2025 (Dec 31, 2025)

Commodore Capital LP

โ€ขCIK: 1831942โ€ขFiling: Q4 2025

**COMMODORE CAPITAL LP** manages $1.5B across a concentrated portfolio of 33 positions. The fund exhibits significant conviction in technology and industrial sectors, with top holdings including RLAY at $143.8M and NTRSO at $99.3M. Further substantial allocations are noted in TYRA ($88.7M), XENE ($80.7M), and SYRE ($78.2M). This structure suggests a focused, high-conviction approach to identifying market leaders.

Total AUM
$1.5B
QoQ Performance
-26.7%
Positions
33
Top 10 Concentration
55.8%
Latest Filing
Q4 2025

Top Holdings Allocation

RLAY
ALKS
TYRA
XENE
SYRE
COGT
RLAY9.6%
ALKS6.6%
TYRA5.9%
XENE5.4%
SYRE5.2%
COGT5.2%
ELVN4.8%
TCE24.6%

๐Ÿ“ˆ Biggest Buys

ANRO
ALTO NEUROSCIENCE INC
NEW
2.2% of portfolio
PALI
PALISADE BIO INC
NEW
1.8% of portfolio
AMLX
AMYLYX PHARMACEUTICALS INC
+38.6%
4.5% of portfolio
REPL
REPLIMUNE GROUP INC
NEW
0.9% of portfolio
SYRE
SPYRE THERAPEUTICS INC
+20.1%
5.2% of portfolio

๐Ÿ“‰ Biggest Sells

COGT
COGENT BIOSCIENCES INC
-69.7%
5.2% of portfolio
TERN
TERNS PHARMACEUTICALS INC
-74.1%
4.0% of portfolio
NUVL
NUVALENT INC
-60.7%
3.7% of portfolio
PTGX
PROTAGONIST THERAPEUTICS INC
-56.1%
2.6% of portfolio
CNTA
CENTESSA PHARMACEUTICALS PLC
-64.9%
1.7% of portfolio

Sector Breakdown

Other100.0%

๐Ÿšช Exited Positionssold since Q3 2025

2GH
MERUS N V
SOLD
$331.9M
AGIO
AGIOS PHARMACEUTICALS INC
SOLD
$93.9M
VRDN
VIRIDIAN THERAPEUTICS INC
SOLD
$69.1M
CDTX
CIDARA THERAPEUTICS INC
SOLD
$56.0M
TNGX
TANGO THERAPEUTICS INC
SOLD
$12.6M
+5 more exited positions

Changes from Q3 2025

NEW6 new positions
โ†‘4 increased
โ†“12 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023